Hollak, Carla E M <br/><br/>
Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.  [electronic resource] 

 -  Blood cells, molecules & diseases  Jan 2010 
 - 41-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1096-0961 
<br/><br/><label>Standard No.: </label>10.1016/j.bcmd.2009.09.006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>1-Deoxynojirimycin--analogs & derivatives<br/>Africa, Northern--epidemiology<br/>Compassionate Use Trials<br/>Drug Contamination--prevention & control<br/>Drugs, Investigational--supply & distribution<br/>Enzyme Inhibitors--therapeutic use<br/>Enzyme Replacement Therapy--statistics & numerical data<br/>Equipment Contamination<br/>Europe--epidemiology<br/>Gaucher Disease--drug therapy<br/>Glucosylceramidase--supply & distribution<br/>Guidelines as Topic<br/>Health Care Rationing<br/>Health Priorities<br/>Humans<br/>International Cooperation<br/>Middle East--epidemiology<br/>Recombinant Proteins--supply & distribution<br/>Vesivirus